Business Wire·Nov 11, 2026, 4:00 PM ET

Teiko Published Approach to Address Problems of Multi-Site Immune Monitoring in Global Oncology Trial

Teiko & iOnctura published a review in Bioanalysis regarding sample stabilization & mass cytometry in global oncology trials.
The approach addresses specimen degradation & slow panel development barriers that historically limited rare immune cell monitoring.
Site-level blood stabilization using TokuKit fixation eliminates the 72-hour live-cell transit window & prevents specimen loss.
Centralized mass cytometry allows qualification of 20+ marker assays in three weeks, significantly faster than the six months required for spectral flow cytometry.
The method is currently applied in three ongoing trials to characterize peripheral immune cell changes during roginolisib treatment alone or combined with standard care.
iOnctura's roginolisib is a conformation-selective PI3K-delta inhibitor targeting the inactive enzyme form to treat solid & hematological malignancies.
Michael Lahn, MD, iOnctura's Chief Medical Officer, stated the solution reduces multinational trial noise & optimizes understanding of drug mechanisms.